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Abstract  
Although fluoroquinolones or other antibiotics are commonly used to prevent bacterial 
infections after hematopoietic cell transplantation (HCT), due to the growing presence of 
multidrug-resistant microorganisms, it is important to identify patients who are more likely to 
benefit from antibacterial prophylaxis. To evaluate risk factors for early bacterial infection 
after allogeneic HCT, we retrospectively analyzed clinical data for 112 consecutive adult 
patients with hematologic malignancies who received transplants without any antibacterial 
prophylaxis. The cumulative incidence of bacterial infection at 30 days after transplantation 
was 16%. Among various pre-transplant factors, only high serum ferritin (>700 ng/mL, 47 
patients) and high C-reactive protein (CRP) (>0.3 mg/dL, 28 patients) levels were 
significantly associated with the development of bacterial infection in a multivariate analysis 
(hazard ratio [95% confidence interval]: ferritin, 4.00 [1.32–12.17]; CRP, 3.64 [1.44–9.20]). 
In addition, septic shock and sepsis with organ failure were exclusively observed in patients 
who had high ferritin and/or high CRP levels. These results suggest that pretransplant serum 
ferritin and CRP levels can be useful markers for predicting the risk of early bacterial 
infection after allogeneic HCT. It may be prudent to limit antibacterial prophylaxis to patients 
with predefined risk factors to ensure the safety of HCT with the use of fewer antibiotics. 
Keywords: antibacterial prophylaxis, fluoroquinolone, bacterial infection, allogeneic 
hematopoietic cell transplantation.
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Introduction 
Bacterial infection is an important cause of mortality and morbidity after autologous or 
allogeneic hematopoietic cell transplantation (HCT).1, 2 When neutropenic patients who 
receive cytotoxic chemotherapy are compared to HCT recipients, the risk of severe bacterial 
infection appears to be considerably higher in the latter because high-dose chemotherapy 
and/or total-body irradiation (TBI) may cause severe mucosal damage that facilitates massive 
bacterial translocation under profound post-transplant immunosuppression. Therefore, the use 
of oral fluoroquinolones (FQs) or other antibiotics as antibacterial prophylaxis is strongly 
considered for HCT recipients, although significant variations have been reported among 
transplant centers and countries.3-5 
Recently, the widespread emergence of FQ-resistant or multidrug-resistant 
microorganisms in hematology-oncology units has been suggested to compromise the 
effectiveness of routine antibacterial prophylaxis with FQs in patients undergoing cytotoxic 
chemotherapy or HCT.6-14 In our center, the isolation rate of FQ-resistant gram-negative 
bacilli was high (57.1%) during a period when FQs were routinely administered as 
antibacterial prophylactic agents; in particular, among isolated Enterobacteriaceae strains, 
66.7%, 33.3%, and 22.2% were resistant to levofloxacin, piperacillin, and ceftazidime, 
respectively.8 In an attempt to reduce the emergence of antibiotic-resistant microorganisms, 
we stopped using any antibacterial prophylaxis in both autologous and allogeneic HCT 
recipients in 2004,8 and found that this discontinuation of FQ prophylaxis, even in the setting 
of myeloablative allogeneic HCT, did not significantly affect early mortality after 
transplantation.15 
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Another approach to balance the safety of HCT with judicious antibiotic use would be 
to limit the use of antibacterial prophylaxis to HCT recipients who are at high risk of 
bacterial infection, since a delay in antibiotic treatment may lead to serious complications 
after infectious episodes in such patients if prophylactic antibiotics are not administered. To 
identify the pretransplant characteristics of patients who are more likely to be susceptible to 
bacterial infection after allogeneic HCT, we conducted a single-center retrospective study 
with the clinical data of 112 consecutive allogeneic transplants for hematologic 
malignancies that were performed without antibacterial prophylaxis. As a potential 
biomarker for predicting bacterial infection, high levels of pretransplant ferritin levels have 
recently been shown to be associated with an increased incidence of bloodstream infection, 
as well as decreased overall survival and increased early mortality.16 In addition, elevated 
pretransplant serum CRP levels have been shown to be associated with an increased 
incidence of bacterial infection in the setting of chemotherapy for acute myeloid leukemia17 
and allogeneic transplantation.18 Sato et al. reported that pretreatment serum CRP levels of 
greater than 0.26 mg/dL were useful for predicting the incidence of documented infection in 
patients who received their first consolidation chemotherapy for acute myeloid leukemia.17 
Since these biomarkers are easy to measure and may be useful in clinical practice, in the 
present study we explored the association between bacterial infection and these biomarkers 
as well as various patient characteristics. 
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Subjects and methods 
Study population 
The medical records of 137 consecutive adult patients with hematologic malignancies who 
underwent T-cell replete allogeneic HCT from September 2004 to March 2009 at Kyoto 
University Hospital were reviewed. Patients who had active infections prior to the 
transplantation procedure (n = 23) and those who had a recent history of autologous or 
allogeneic HCT within 1 year (n = 2) were excluded; thus, a total of 112 patients were 
included in the analysis, without any duplication of subjects. Patients were considered to have 
standard-risk disease if they received a transplant without prior chemotherapy or in complete 
remission, while those who received a transplant in any other status were considered to have 
high-risk disease. This study was approved by the Ethics Committee of Kyoto University 
Graduate School and the Faculty of Medicine. Written informed consent for the 
transplantation protocol was obtained from all of the patients. 
 
Prophylaxis, monitoring, and diagnosis of infection 
A central venous catheter was inserted in the subclavian vein prior to the beginning of the 
conditioning regimens for all patients. Each patient was isolated in a single room equipped 
with a high-efficiency particulate air filter system from a day before the transplantation until 
at least 4 weeks after transplantation. Each patient was then maintained on a low-microbial 
diet and asked to take strict control measures under the supervision of the ward staff to 
prevent the acquisition of nosocomial pathogens. No bacterial prophylaxis was prescribed for 
these patients according to our institutional protocols.8 Intravenous antibiotics with 
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anti-pseudomonal activity were promptly administered in response to episodes of febrile 
neutropenia or suspected bacterial infections. Trimethoprim-sulfamethoxazole (trimethoprim; 
160 mg/day, three times a week) was administered as prophylactic therapy for Pneumocystis 
jiroveci pneumonia from the day of admission until the day of transplantation, and this 
prophylaxis was reinitiated after the day of neutrophil engraftment. All patients received 200 
or 400 mg of fluconazole and 400-1000 mg of acyclovir per day as prophylactic agents from 
the conditioning period until 30 days after transplantation. Prophylactic fluconazole and 
acyclovir were usually continued when patients were receiving steroid therapy for acute or 
chronic graft-versus-host disease. For each febrile episode, 1 or 2 sets of blood samples were 
cultured, and cultures of specimens other than blood specimens and imaging examinations to 
search for the focus of infection were performed according to the clinician's judgment. 
Microbiologically documented infections included the presence of bloodstream bacterial 
infection or any other bacterial infection. Bloodstream bacterial infection was diagnosed 
when at least 1 of the following criteria was met: (1) the culture of blood obtained during a 
febrile episode tested positive at least once for bacterial organisms other than common skin 
contaminants, (2) the culture of blood obtained during a febrile episode tested positive for the 
same common skin contaminant in independent analysis conducted within an interval of 72 h, 
and (3) the blood culture tested positive at least once for a common skin contaminant, and the 
patient was diagnosed with septicemia with hypotension (systolic blood pressure, <90 mm 
Hg) and disseminated intravascular coagulation. Infections other than bloodstream infection 
were diagnosed when the following criteria were met: (1) sputum, urine, or stool samples 
were found to contain pathogenic bacteria on at least 2 occasions, and (2) the patient showed 
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symptoms of infection corresponding to those specimens. Septic shock and sepsis with organ 
failure were defined as severe infection. 
 
Measurement of serum biomarkers (serum ferritin and C-reactive proteins) 
Both serum ferritin and CRP levels were measured using peripheral blood samples obtained 
just prior to the start of the conditioning regimen. The serum ferritin concentration was 
measured by an immunoenzymometric assay (AIA-PACK FER, Tosoh Corporation, Tokyo, 
Japan) (normal range; ≤150 ng/mL), and the serum CRP concentration was measured by a 
latex agglutination assay (N-Assay LA CRP-S, Nittobo, Tokyo, Japan) (normal range; ≤0.2 
mg/dL), according to the respective manufacturer’s instructions. 
 
Statistical analysis 
The primary endpoint was the cumulative incidence of documented bacterial infections 
during the first 30 days after transplantation. Overall survival and treatment-related mortality 
were also analyzed as secondary endpoints. To eliminate the effect of a competing risk, the 
cumulative incidence was assessed using methods described elsewhere.19 In the analysis of 
the cumulative incidence of bacterial infections and treatment-related mortality, a competing 
event was defined as death without an event of interest. The overall survival was estimated 
using the Kaplan-Meier method. We applied Fine and Gray’s proportional-hazards model for 
the sub-distribution of a competing risk to analyze the cumulative incidence of bacterial 
infection and treatment-related mortality, and the Cox proportional-hazards model for that of 
overall survival.20 Factors with P values of less than 0.10 in the univariate analysis were 
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included in the multivariate analysis. Factors evaluated in the analysis included the 
recipient’s age (≤50 or >50), recipient’s sex (female or male), diagnosis (myeloid or 
lymphoid malignancies), disease status at transplant (standard risk or high risk), duration 
from diagnosis to transplant (≤1 or >1 year), duration from the last pretransplant cytotoxic 
chemotherapy to conditioning of transplant (no history of prior chemotherapy or >2, or ≤2 
months), number of courses of prior cytotoxic chemotherapy (≤5 or >5), source of stem cells 
(related bone marrow or peripheral blood, unrelated bone marrow, or unrelated cord blood), 
conditioning regimen (conventional or reduced-intensity regimen), use of granulocyte 
colony-stimulating factor (G-CSF) (yes or no), serum ferritin levels (≤700 ng/mL, >700 
ng/mL, or unknown), and serum CRP levels (≤0.3 mg/dL or >0.3 mg/dL). We assessed the 
interaction between ferritin and CRP levels, using interaction terms between a ferritin 
category with scores of 0 (ferritin ≤700 ng/mL) and 1 (ferritin >700 ng/mL) and a CRP 
category with scores of 0 (CRP ≤0.3 mg/dL) and 1 (CRP >0.3 mg/dL). The cutoff point for 
the ferritin levels was the median value and that for the CRP levels was the higher tertile 
value. The correlation between ferritin and CRP levels was also tested by Pearson’s 
correlation coefficient. P values of less than 0.05 were considered statistically significant. All 
analyses were conducted using Stata software version 11 (StataCorp., College Station, TX, 
USA).
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Results 
Patient characteristics 
The patient characteristics are shown in Table 1. The median age of the patients was 47 years 
(range, 18–66 years). The primary diseases in these patients were as follows: acute myeloid 
leukemia in 46 patients, acute lymphoblastic leukemia in 11, myelodysplastic syndrome in 16, 
chronic myelogenous leukemia in 4, non-Hodgkin lymphoma in 19, adult T-cell 
leukemia/lymphoma in 10, myeloproliferative disorder in 4, and plasma-cell myeloma in 2. 
Sixty-six patients (58.9%) had standard-risk disease. The source of stem cells used for HCT 
was related bone marrow or peripheral blood in 40 patients (35.7%), unrelated bone marrow 
in 52 (46.4%), and unrelated cord blood in 20 (17.9%). A conventional myeloablative 
regimen was used in 54 patients (48.2%), and G-CSF was used after HCT in 57 patients 
(50.9%). The number of patients with pretransplant serum ferritin levels of ≤700 ng/mL, 
>700 ng/mL, and unavailable were 49, 47, and 16, respectively, and the number of those with 
pretransplant serum CRP levels of ≤0.3 mg/dL and >0.3 mg/dL were 84 and 28, respectively. 
 
Documented bacterial infections 
A total of 19 episodes of bacterial infections were documented during the first 30 days after 
HCT; these included 18 episodes of bloodstream infections and 1 of pneumonia. No patient 
had more than 1 episode of bacterial infection within 30 days after HCT. The bacterial 
organisms associated with the documented infections are listed in Table 2. The detected 
bacterial organisms were mainly gram-negative bacilli (n = 16, 84.2%), 15 of which (93.6%) 
were sensitive to FQs. 
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The cumulative incidence of bacterial infections was 16% (95% confidence interval 
[CI], 10%–24%). Among confounding factors that were potentially associated with bacterial 
infection, only high pretransplant serum ferritin (>700 ng/mL vs. ≤700 ng/mL) and high CRP 
(>0.3 mg/dL vs. ≤0.3 mg/dL) levels were significantly associated with the development of 
bacterial infection in the multivariate analysis (hazard ratio [95% CI]: ferritin, 3.97 
[1.35–11.69], P = 0.012; CRP, 3.63 [1.45–9.10], P = 0.006) (Table 3). Even when serum 
ferritin and CRP levels were treated as continuous variables, their impact remained 
significant. Although there was no correlation between ferritin and CRP levels (P=0.062), we 
analyzed the impact of high ferritin levels in subgroups of patients with either high (>0.3 
mg/dL) or low CRP levels (≤0.3 mg/dL), to exclude the effect of inflammation on ferritin 
levels. We obtained almost consistent results in both groups (hazard ratio [95% CI]: CRP 
>0.3 mg/dL, 3.67 [0.87-15.63], P = 0.078; CRP ≤0.3 mg/dL, 4.12 [0.86-19.64], P = 0.076). 
Further, no interaction was observed between the ferritin and CRP categories (P = 0.949). 
Next, we re-evaluated the risk of bacterial infection with the combination of these 2 risk 
factors (ferritin and CRP levels). Figure 1 shows the cumulative incidence of bacterial 
infection for patients divided into 3 risk groups according to this model. The cumulative 
incidences of bacterial infections were 5.3% (95% CI; 1.0–15.7%) in patients without any 
risk factors (n = 39), 20.5% (95% CI; 10.1–33.3%) in those with 1 factor (n = 44), and 53.8% 
(95% CI; 24.8–76.0%) in those with 2 factors (n = 13). The hazard ratios for 1 and 2 risk 
factors relative to no risk factors in the multivariate analysis were 4.04 (95% CI, 0.88–18.62) 
and 14.68 (3.02–71.30), respectively. Among patients with bacterial infections, septic shock 
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or organ failure was observed in 1 patient with 2 risk factors and 4 patients with 1 risk factor, 
but not in any patients with no risk factors. 
 
Overall survival and treatment-related mortality 
Next, we evaluated the impact of the ferritin and CRP levels on other endpoints in 96 patients 
for whom data on ferritin levels were available (Figures 2 and 3). The median duration of 
follow-up was 23 months (range, 2.2-54.9). With regard to overall survival, only a high 
ferritin level (hazard ratio [95% CI]: 2.47 [1.19–5.11], P = 0.015) and a duration of less than 
2 months from the last cytotoxic chemotherapy to the conditioning of transplant (hazard ratio 
[95% CI]: 2.16 [1.10–4.26], P = 0.026) were significant variables in the multivariate analysis. 
The causes of death are shown in Table 4. Interestingly, 7 patients among those with high 
ferritin levels died within 100 days (causes of death: acute graft-versus-host diseases, n = 2; 
infection, n = 3; hepatic veno-occlusive disease, n = 1; organ failure, n = 1), while none of the 
patients with low ferritin levels died. With regard to treatment-related mortality, only ferritin 
and CRP levels were adversely associated with higher treatment-related mortality in the 
multivariate analysis (hazard ratio [95% CI]: ferritin, 5.21 [1.41–19.30], P = 0.013; CRP, 
5.76 [1.70–19.48], P = 0.005). 
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Discussion 
In our cohort of 112 patients with hematologic malignancies who underwent allogeneic HCT 
without antibacterial prophylaxis, we found that only high serum ferritin and high CRP levels 
prior to transplantation were significant risk factors for the post-transplant development of 
bacterial infection; patients with high ferritin levels and those with high CRP levels had an 
almost 4-fold higher risk of bacterial infection than those with low ferritin levels or those 
with low CRP levels. In addition, while severe complications associated with bacterial 
infection were observed in 5 patients with high ferritin levels and/or high CRP levels, none 
were seen in patients with low ferritin and low CRP levels. These results suggest that 
pretransplant serum ferritin and CRP levels may be useful markers for predicting the risk of 
early bacterial complications after allogeneic HCT. 
 
An association between iron overload and bacterial or fungal infection has been shown 
in hereditary and secondary hemochromatosis.21, 22 With regard to HCT, Pullarkat et al. 
reported that ferritin levels of ≥1000 ng/mL were associated with a 2-fold higher risk of 
bloodstream infection compared to patients with ferritin levels of <1000 ng/mL in 
myeloablative HCT.16 In agreement with their finding, in the present study, ferritin levels of 
>700 ng/mL were associated with a 4-fold increased risk compared to the risk in patients with 
levels of ≤700 ng/mL. An increase in plasma non-transferrin-bound iron (NTBI) is 
considered to play an important role in the adverse effect of iron overload on bacterial 
infection. Under normal conditions, toxic reactions due to the production of NTBI are 
prevented by circulating transferrin, which forms a compound with Fe3+.23 However, plasma 
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NTBI increases to a measurable level in patients with iron overload because transferrin is 
almost saturated with Fe3+.24 The inhibition of iron utilization in erythrocytes by 
chemotherapeutic agents and irradiation further increases NTBI levels.25 Hydroxyl radical 
reactions by NTBI exacerbate mucosal damage caused by chemotherapeutic agents and 
irradiation, which allows bacterial organisms to enter through the circulation.26 In addition, 
iron is an important nutrient for the proliferation of bacteria and fungi.27 In the HCT setting, 
the ability of NTBI to induce the proliferation of Staphylococcus epidermidis has been 
demonstrated in an in vitro study using the serum of patients undergoing HCT.28 
 
In addition to the adverse impact of iron overload on early infection-related 
complications, several studies have suggested that high ferritin levels are adversely associated 
with overall survival and treatment-related mortality.16, 29-31 In agreement with these studies, 
our results demonstrated that high ferritin levels are associated with a 2.5-fold increased risk 
of overall mortality and a 5-fold increased risk of higher treatment-related mortality, 
compared with low ferritin levels. These studies collectively suggest that iron overload is an 
important and strong prognostic factor in various clinical outcomes of allogeneic HCT.  
 
Recently, an association between iron chelation therapy and longer overall survival was 
demonstrated in patients with MDS or severe anemia requiring multiple blood transfusions,32, 
33 and adequate iron chelation therapy is recommended for such patients.34 The 
administration of oral iron chelating agents such as deferasirox may be an attractive treatment 
for iron-overloaded patients compared to deferoxamine, which requires subcutaneous or 
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intravenous administration. However, the optimal dosage and timing for the administration of 
deferasirox in allogeneic HCT should be carefully determined in future studies because its 
renal and gastrointestinal side effects may exacerbate complications of HCT. 
 
At present, only one report has referred to the association between pretransplant CRP 
levels and transplant outcomes.18 In that report, pretransplant CRP levels had a marginally 
significant association with infection within 100 days after reduced-intensity HCT, while 
other confounding factors, including age, disease status, hematopoietic cell 
transplantation-specific comorbidity index (HCT-CI), and performance status, had no 
association; this result is consistent with our present findings. One possible explanation of 
these findings is that the slightly elevated CRP levels might have reflected minute 
inflammation, which may represent the presence of latent bacterial infection with negative 
clinical signs and negative results in pretransplant screening tests, such as X-ray or CT scans. 
Undetectable bacterial organisms colonized under bacteriostatic conditions before transplant 
might have rapidly proliferated in the post-transplant neutropenic and immunosuppressive 
state. Therefore, even if no bacterial infection is detected before transplant in screening tests, 
latent bacterial infection should be considered in patients with high CRP levels. With regard 
to treatment-related mortality, an elevated pretransplant CRP level was found to be a 
significant risk factor in our study, consistent with a previous report.18 The reason for the 
worse treatment-related mortality in patients with elevated pretransplant CRP levels remains 
unclear and needs to be clarified in future studies. 
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To ensure the safety of allogeneic HCT with the limited use of antibacterial agents, the 
selective prophylactic administration of antibacterial agents such as FQs only to patients at 
high risk of bacterial infection may be effective. In the present study, gram-negative bacilli 
that were highly sensitive to FQs (93.6%) were the main bacterial organisms isolated, which 
suggests that these infections may have been prevented by the prophylactic administration of 
FQs in our center. However, this approach may be effective only if most of the bacterial 
isolates at the transplant center were sufficiently sensitive to these prophylactic antibiotics. In 
future studies, it would be worthwhile to evaluate whether the incidence of early bacterial 
infection can be reduced by the prophylactic administration of antibiotics in patients with 
predefined risk factors such as high ferritin levels or high CRP levels. Iron chelation therapy 
before HCT is another intriguing strategy that is worthy of future evaluation. 
 
The present study had several limitations. The retrospective study design, small sample 
size, and heterogeneous background of diseases and transplantation procedures may have 
biased the results. In addition, HCT-CI, including the performance status, was not evaluated 
in this cohort due to a lack of adequate information. Further, the impact of serum ferritin 
levels on the outcomes should be interpreted with caution. Although we consistently 
determined that high ferritin levels have an adverse impact on early bacterial infection 
regardless of CRP levels, serum ferritin levels can be affected by conditions associated with 
other diseases.35 In a future study, it may be worthwhile to quantify iron overload by other 
methods, such as magnetic resonance imaging of the liver,36 and to re-analyze the effect of 
iron content on the outcome. 
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In conclusion, the present results suggest that pretransplant serum ferritin and CRP 
levels, which can be easily measured in various centers, may be useful markers for predicting 
the risk of early bacterial complications after allogeneic HCT. However, larger prospective 
studies are warranted to validate our findings and further research is needed to identify other 
biomarkers that may be associated with the development of post-transplant bacterial 
complications.  
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TABLES 
Table 1 Patient characteristics 
Category Patients 
    n = 112 
Age, years   
 Median (range) 47 (18-66) 
Sex, n (%)   
Male 49 (43.8)  
Female 63 (56.3) 
Diagnosis, n (%)   
 Acute myeloid leukemia 46 (41.1) 
 Acute lymphoblastic leukemia 11 (9.8) 
 Myelodysplastic syndrome 16 (14.3) 
 Chronic myelogenous leukemia 4 (3.6) 
 Non-Hodgkin lymphoma 19 (17.0) 
 Adult T-cell leukemia/lymphoma 10 (8.9) 
 Myeloproliferative disorder 4 (3.6) 
 Plasma-cell myeloma 2 (1.8) 
Disease status at transplant, n (%)   
Standard risk 66 (58.9)  
High risk 46 (41.1) 
Source of stem cells, n (%)   
Related bone marrow or peripheral blood 40 (35.7) 
Unrelated bone marrow 52 (46.4) 
 
Unrelated cord blood 20 (17.9) 
Conditioning regimen, n (%)   
Conventional-intensity regimen 54 (48.2) 
  BU/CY 10  
  TBI/CY based regimen 44  
Reduced-intensity regimen 58 (51.8) 
  Flu/BU +- TBI 23  
  Flu/Mel +- TBI 34  
 
  Flu/TT 1  
Use of G-CSF, n (%)   
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Yes 57 (50.9)  
No 55 (49.1) 
Duration from diagnosis to transplant, n (%)   
 ≤1 year 57 (50.9) 
 >1 year 55 (49.1) 
Duration from the last pretransplant cytotoxic 
chemotherapy to conditioning of transplant, n (%) 
  
 No history of prior cytotoxic chemotherapy or 
>2 months 
68 (60.7) 
 ≤2 months 44 (39.3) 
Number of courses of prior cytotoxic 
chemotherapy, n (%) 
  
 ≤5 courses 60 (53.6) 
 >5 courses 52 (46.4) 
Pretransplant serum ferritin level (ng/mL)   
 Median (range) 694.6 (34.7-12079.1) 
Pretransplant serum CRP level (mg/dL)   
  Median (range) 0.1 (0.0-4.6) 
 
Abbreviations: BU = busulfan; CY = cyclophosphamide; TBI = total-body irradiation; Flu = 
fludarabine; Mel = melphalan; TT = thiotepa, G-CSF = granulocyte colony-stimulating factor. 
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Table 2 Documented bacterial organisms within 30 days after transplantation 
 
Category Bacterial isolates 
  
Gram-positive cocci (n) Enterococcus faecium (2)  
 Streptococcus epidermidis (1) 
  
Gram-negative bacilli (n) Klebsiella pneumoniae (5) 
 Escherichia coli (4) 
 Pseudomonas aeruginosa (2) 
 Klebsiella oxytoca (1) 
 Enterobacter cloacae (1) 
 Capnocytophaga species (1) 
 Prevotella intermedia (1) 
 Bacteroides thetaiotaomicron (1) 
  
 
P. aeruginosa was detected in the sputum of one patient with pneumonia. Other organisms were 
detected in blood culture bottles. 
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 Table 3 Univariate and multivariate analyses of factors that are potentially associated with documented bacterial infection 
Category Univariate Analysis Multivariate Analysis 
    
Number 
hazard ratio (95% CI) P value hazard ratio (95% CI) P value 
Age, years      
 ≤ 50 10/64 1.00  Reference   
 >50 9/48 1.27 (0.51-3.17) 0.608    
Sex      
 Female 9/49 1.00  Reference   
 Male 10/63 0.80 (0.32-2.00) 0.632    
Diagnosis      
 Myeloid malignancies 13/72 1.00  Reference   
 Lymphoid malignancies 6/40 0.86 (0.33-2.26) 0.766    
Disease status at transplant      
 Standard risk 11/66 1.00  Reference   
 High risk 8/46 1.13 (0.45-2.84) 0.795    
Source of stem cells      
 Related bone marrow or peripheral blood 6/40 1.00  Reference   
 Unrelated bone marrow 8/52 0.88 (0.30-2.59) 0.816    
 Unrelated cord blood 5/20 1.84 (0.56-6.05) 0.318    
Conditioning regimen      
 Conventional-intensity regimen 8/54 1.00  Reference   
 Reduced-intensity regimen 11/58 1.48 (0.57-3.79) 0.419    
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Use of G-CSF      
 No 10/55 1.00  Reference   
 Yes 9/57 0.98 (0.39-2.45) 0.966    
Duration from diagnosis to transplant      
 ≤1 year 9/57 1.00  Reference   
 >1 year 10/55 1.33 (0.53-3.34) 0.550    
Duration from the last pretransplant cytotoxic 
chemotherapy to conditioning of transplant  
    
 
No history of prior cytotoxic chemotherapy or 
>2 months  13/68 
1.00  Reference   
 ≤2 months 6/44 0.76 (0.29-2.03) 0.589    
Number of courses of prior cytotoxic 
chemotherapy  
    
 ≤5 courses 9/60 1.00  Reference   
 >5 courses 10/52 1.44 (0.57-3.64) 0.441   
Serum ferritin level      
 ≤700 ng/mL 5/49 1.00  Reference 1.00  Reference 
 >700 ng/mL 14/47 4.04 (1.35-12.05) 0.012  3.97 (1.35-11.69) 0.012  
 Not available 0/16 - - - - 
Serum CRP level      
 ≤0.3 mg/dL 10/84 1.00  Reference 1.00  Reference 
 >0.3 mg/dL 9/28 3.38 (1.36-8.39) 0.009  3.63 (1.45-9.10) 0.006  
Abbreviations: CI = confidence intervals; G-CSF = granulocyte colony-stimulating factor.
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Table 4 Causes of death 
Category 
Low ferritin group 
 (≤700 ng/mL) (n = 49) 
High ferritin group  
(>700 ng/mL) (n = 47) 
Within 100 days after transplant   
Infection 0 2 (29%) 
Organ failure 0 2 (29%) 
Graft-versus-host disease 0 2 (29%) 
Hepatic veno-occlusive disease  0 1 (14%) 
Total 0 7 
   
More than 100 days after 
transplant   
Relapse 9 (82%) 12 (75%) 
Infection 1 (9%) 2 (13%) 
Organ failure 1 (9%) 0 
Idiopathic pneumonia syndrome 0 1 (6%) 
Bleeding 0 1 (6%) 
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FIGURE LEGENDS 
Figure 1 
Cumulative incidence of documented bacterial infection within 30 days after 
transplantation. A) Solid black line, patients with low ferritin levels (≤700 ng/mL) (n = 
49); gray line, patients with high ferritin levels (>700 ng/mL) (n = 47), B) Solid black 
line, patients with low CRP levels (≤0.3 mg/dL) (n = 84); gray line, patients with high 
CRP levels (>0.3 mg/dL) (n = 28), C) Solid black line, patients with low ferritin (≤700 
ng/mL) and low CRP levels (≤0.3 mg/dL) (n = 39); gray line, patients with low ferritin 
and high CRP levels (>0.3 mg/dL) or high ferritin (>700 ng/mL) and low CRP levels (n 
= 44); dotted black line, patients with high ferritin and high CRP levels (n = 13). 
 
Figure 2 
Kaplan-Meier estimate of overall survival after transplantation. A) Solid black line, 
patients with low ferritin levels (≤700 ng/mL) (n = 49); gray line, patients with high 
ferritin levels (>700 ng/mL) (n = 47), B) Solid black line, patients with low CRP levels 
(≤0.3 mg/dL) (n = 73); gray line, patients with high CRP levels (>0.3 mg/dL) (n = 23). 
Figure 3 
Cumulative incidence of treatment-related mortality after transplantation. A) Solid black 
line, patients with low ferritin levels (≤700 ng/mL) (n = 49); gray line, patients with 
high ferritin levels (>700 ng/mL) (n = 47), B) Solid black line, patients with low CRP 
levels (≤0.3 mg/dL) (n = 73); gray line, patients with high CRP levels (>0.3 mg/dL) (n = 
23). 
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